Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations

Thomas Van den Broeck; Roderick C.N. van den Bergh; Erik Briers; Philip Cornford; Marcus Cumberbatch; Derya Tilki; Maria De Santis; Stefano Fanti; Nicola Fossati; Silke Gillessen; Jeremy P. Grummet; Ann M. Henry; Michael Lardas; Matthew Liew; Malcolm Mason; Lisa Moris; Ivo G. Schoots; Theodorus van der Kwast; Henk van der Poel; Thomas Wiegel; Peter Paul M. Willemse; Olivier Rouvière; Thomas B. Lam; Nicolas Mottet

doi:10.1016/j.euf.2019.06.004

Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations

Thomas Van den Broeck^*, Roderick C.N. van den Bergh, Erik Briers, Philip Cornford, Marcus Cumberbatch, Derya Tilki, Maria De Santis, Stefano Fanti, Nicola Fossati, Silke Gillessen, Jeremy P. Grummet, Ann M. Henry, Michael Lardas, Matthew Liew, Malcolm Mason, Lisa Moris, Ivo G. Schoots, Theodorus van der Kwast, Henk van der Poel, Thomas WiegelPeter Paul M. Willemse, Olivier Rouvière, Thomas B. Lam, Nicolas Mottet

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. Patient summary: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions. The EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guidelines panel recommends stratifying patients experiencing biochemical recurrence (BCR) after primary treatment for localized prostate cancer into EAU low-risk and high-risk BCR groups. Each patient's risk profile and life expectancy should be considered when discussing the benefits and toxicities of salvage treatments.

Original language	English
Journal	European Urology Focus
Early online date	24 Jun 2019
DOIs	https://doi.org/10.1016/j.euf.2019.06.004
Publication status	Published - 2019

Keywords

Biochemical recurrence
European Association of Urology
Gleason score
Guidelines
Prognostic factors
Prostate cancer
PSA kinetics
Radical prostatectomy
Radiotherapy

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.euf.2019.06.004

Cite this

Van den Broeck, T., van den Bergh, R. C. N., Briers, E., Cornford, P., Cumberbatch, M., Tilki, D., De Santis, M., Fanti, S., Fossati, N., Gillessen, S., Grummet, J. P., Henry, A. M., Lardas, M., Liew, M., Mason, M., Moris, L., Schoots, I. G., van der Kwast, T., van der Poel, H., ... Mottet, N. (2019). Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. European Urology Focus. https://doi.org/10.1016/j.euf.2019.06.004

@article{eeff894ebca34bc6998e493ad9d88037,

title = "Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations",

abstract = "Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. Patient summary: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions. The EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guidelines panel recommends stratifying patients experiencing biochemical recurrence (BCR) after primary treatment for localized prostate cancer into EAU low-risk and high-risk BCR groups. Each patient's risk profile and life expectancy should be considered when discussing the benefits and toxicities of salvage treatments.",

keywords = "Biochemical recurrence, European Association of Urology, Gleason score, Guidelines, Prognostic factors, Prostate cancer, PSA kinetics, Radical prostatectomy, Radiotherapy",

author = "{Van den Broeck}, Thomas and {van den Bergh}, {Roderick C.N.} and Erik Briers and Philip Cornford and Marcus Cumberbatch and Derya Tilki and {De Santis}, Maria and Stefano Fanti and Nicola Fossati and Silke Gillessen and Grummet, {Jeremy P.} and Henry, {Ann M.} and Michael Lardas and Matthew Liew and Malcolm Mason and Lisa Moris and Schoots, {Ivo G.} and {van der Kwast}, Theodorus and {van der Poel}, Henk and Thomas Wiegel and Willemse, {Peter Paul M.} and Olivier Rouvi{\`e}re and Lam, {Thomas B.} and Nicolas Mottet",

year = "2019",

doi = "10.1016/j.euf.2019.06.004",

language = "English",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier BV",

}

Van den Broeck, T, van den Bergh, RCN, Briers, E, Cornford, P, Cumberbatch, M, Tilki, D, De Santis, M, Fanti, S, Fossati, N, Gillessen, S, Grummet, JP, Henry, AM, Lardas, M, Liew, M, Mason, M, Moris, L, Schoots, IG, van der Kwast, T, van der Poel, H, Wiegel, T, Willemse, PPM, Rouvière, O, Lam, TB & Mottet, N 2019, 'Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations', European Urology Focus. https://doi.org/10.1016/j.euf.2019.06.004

TY - JOUR

T1 - Biochemical Recurrence in Prostate Cancer

T2 - The European Association of Urology Prostate Cancer Guidelines Panel Recommendations

AU - Van den Broeck, Thomas

AU - van den Bergh, Roderick C.N.

AU - Briers, Erik

AU - Cornford, Philip

AU - Cumberbatch, Marcus

AU - Tilki, Derya

AU - De Santis, Maria

AU - Fanti, Stefano

AU - Fossati, Nicola

AU - Gillessen, Silke

AU - Grummet, Jeremy P.

AU - Henry, Ann M.

AU - Lardas, Michael

AU - Liew, Matthew

AU - Mason, Malcolm

AU - Moris, Lisa

AU - Schoots, Ivo G.

AU - van der Kwast, Theodorus

AU - van der Poel, Henk

AU - Wiegel, Thomas

AU - Willemse, Peter Paul M.

AU - Rouvière, Olivier

AU - Lam, Thomas B.

AU - Mottet, Nicolas

PY - 2019

Y1 - 2019

N2 - Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. Patient summary: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions. The EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guidelines panel recommends stratifying patients experiencing biochemical recurrence (BCR) after primary treatment for localized prostate cancer into EAU low-risk and high-risk BCR groups. Each patient's risk profile and life expectancy should be considered when discussing the benefits and toxicities of salvage treatments.

AB - Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. Patient summary: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions. The EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guidelines panel recommends stratifying patients experiencing biochemical recurrence (BCR) after primary treatment for localized prostate cancer into EAU low-risk and high-risk BCR groups. Each patient's risk profile and life expectancy should be considered when discussing the benefits and toxicities of salvage treatments.

KW - Biochemical recurrence

KW - European Association of Urology

KW - Gleason score

KW - Guidelines

KW - Prognostic factors

KW - Prostate cancer

KW - PSA kinetics

KW - Radical prostatectomy

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85067674484&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2019.06.004

DO - 10.1016/j.euf.2019.06.004

M3 - Article

AN - SCOPUS:85067674484

SN - 2405-4569

JO - European Urology Focus

JF - European Urology Focus

ER -

Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this